StockData

Intellia Therapeutics vs Wave Life Sciences

NTLA and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NTLA and WVE compare

Intellia Therapeutics is the larger company, worth 2.4 times as much as Wave Life Sciences ($1.4B against $566M).

Wave Life Sciences keeps more of each dollar of sales as profit, with a net margin of −297% compared with −672% at Intellia Therapeutics.

Wave Life Sciences scores higher on the StockData Score (10 against 8 for Intellia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNTLAWVE
Size and price
Market cap$1.4B$566M
Share price$9.86$2.87
Change, 1 year13.7%−57.0%
Change, 5 years−91.3%−28.1%
Beta (5Y)1.641.84
Employees377317
StockData Score
Total score810 (better)
Valuation score13 (better)
Growth score11
Performance score11
Health score55
Dividend score00
Valuation
P/S23.2×8.0× (better)
P/B1.9×1.4× (better)
FCF yield−25.2% (better)−36.8%
Fair value$9.05$5.23
Margin of safety−8.9%45.1% (better)
Growth
Revenue growth (TTM)12.6%–
Revenue growth, 5Y average3.1%16.3% (better)
Profitability
Operating margin−712%−321% (better)
Net margin−672%−297% (better)
FCF margin−586%−294% (better)
Return on equity−6425%−80.0% (better)
Financial health
Debt / equity0.000.00
Current ratio6.658.38 (better)
Altman Z-score0.91 (better)−1.27
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions103%92.6%
Held by insiders2.0%23.1%
Insider net buying, 12 months−$869K$66.5M (better)
Superinvestors holding–1
Short interest, % of float32.3%13.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.